GlassScriptPhysician profile
Shea Thomas Sims
NPI 1730677675
$7,135.36
in general payments reported to CMS, 2019-2025
52 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,042 · 2022: $3,118 · 2023: $176 · 2024: $558 · 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.40 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $990.28 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $781.79 | 2021-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $603.48 | 2021-2025 | Jardiance |
| Amgen INC. | $568.23 | 2021-2025 | Prolia, Evenity, Enbrel |
| Abbvie INC. | $499.83 | 2021-2025 | |
| Mylan Specialty L.P. | $374.51 | 2021-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $294.34 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $268.44 | 2021-2022 | |
| Ucb, INC. | $228.20 | 2024-2025 | Bimzelx |
| Grifols USA, LLC | $213.93 | 2021-2022 | |
| Genentech USA, INC. | $189.05 | 2022-2025 | Actemra |
| Genzyme Corporation | $153.54 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $128.83 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.71 | 2022-2025 | |
| Pfizer INC. | $104.09 | 2021-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shea Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.